Rocket Doctor AI Triples U.S. Patient Visits, Expands to 24M Covered…

Event summary

Q2 2026 revenue grew 43% YoY to $734,028, with U.S. patient visits tripling QoQ to 3,911.
Expanded U.S. in-network reach to 24M covered lives across California, New York, and Maryland.
Gross margin declined to 65% from 75% QoQ due to U.S. operational scaling costs.
Raised $3.26M in convertible debenture financing to support U.S. expansion.
Achieved SOC 2 Type 1 compliance, validating security and operational controls.

The big picture

Rocket Doctor AI's aggressive U.S. expansion reflects the growing demand for scalable virtual care solutions, particularly among Medicaid and Medicare populations. The company's ability to secure payer agreements and NIH funding validates its physician-led AI approach, but operational execution will determine whether it can capitalize on this momentum. The telehealth sector's shift toward value-based care models positions Rocket Doctor AI to capture market share, though competition and regulatory hurdles remain significant.

What we're watching

Revenue Recognition Lag: How the cash-basis revenue recognition in the U.S. will affect reported financials in coming quarters.
Provider Onboarding: Whether Rocket Doctor AI can sustain its rapid U.S. expansion amid credentialing bottlenecks.
AI Monetization: The pace at which the company can commercialize its AI-driven clinical workflow optimizations.